2. Immunology/Inflammation
  3. IRAK
  4. JH-X-119-01

JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

JH-X-119-01

JH-X-119-01 構造式

CAS 番号 : 2227368-54-7

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 198 在庫あり
Solution
10 mM * 1 mL in DMSO USD 198 在庫あり
Solid
5 mg $180 在庫あり
10 mg $270 在庫あり
25 mg $490 在庫あり
50 mg $730 在庫あり
100 mg $990 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Other Forms of JH-X-119-01:

JH-X-119-01 関連抗体

Top Publications Citing Use of Products

IRAK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
IRAK1 IRAK3 IRAK4

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice[1]. JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC50 of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM[2].

IC50 & Target[2]

IRAK-1

9 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
OCI-LY19 EC50
0.59 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-LY19 EC50
0.59 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-LY19 EC50
0.59 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY19 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly3 EC50
9.72 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly3 EC50
9.72 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly3 EC50
9.72 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY3 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly7 EC50
2.39 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly7 EC50
2.39 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
OCI-Ly7 EC50
2.39 3
Compound: 1; JH-X-119-01
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human OCILY7 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
Ramos EC50
1.79 3
Compound: 1; JH-X-119-01
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
Ramos EC50
1.79 3
Compound: 1; JH-X-119-01
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
RPMI-8226 EC50
5.13 3
Compound: 1; JH-X-119-01
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
RPMI-8226 EC50
5.13 3
Compound: 1; JH-X-119-01
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
RPMI-8226 EC50
5.13 3
Compound: 1; JH-X-119-01
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human RPMI-8226 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
Ramos EC50
1.79 3
Compound: 1; JH-X-119-01
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human Ramos cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
TMD8 EC50
2.4 3
Compound: 1; JH-X-119-01
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
TMD8 EC50
2.4 3
Compound: 1; JH-X-119-01
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
TMD8 EC50
2.4 3
Compound: 1; JH-X-119-01
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
Cytotoxicity against human TMD8 cells expressing MYD88 mutant assessed as cell killing measured after 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 33214835]
体外実験

JH-X-119-01 (10 μM) decreases phosphorylation of NF-κB and mRNA levels of IL-6 and TNFα in LPS-treated macrophages in vitro. JH-X-119-01 selectively inhibits IRAK1 phosphorylation[1].? JH-X-119-01 exhibits off-target inhibition of only two additional kinases, YSK4 and MEK3. Dose response analysis reveals an IC50 of 57 nM for YSK4[2].? JH-X-119-01 shows moderate cell killing effects in a panel of Waldenstr?m’s macroglobulinemia (WM) cells, Diffused Large B-cell Lymphoma (DLBCL) cells, and lymphoma cells expressing mutant MYD88, with EC50s ranging from 0.59 to 9.72 μM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JH-X-119-01 関連抗体

Western Blot Analysis[1]

Cell Line: RAW 264.7 cells and THP-1 cells
Concentration: 10 μM
Incubation Time: 15 minutes
Result: Decreased LPS (100 ng/mL)-induced phosphorylation of IκBα and NF-κB-P65.
体内実験

JH-X-119-01 improves survival and decreases immunopathies of LPS-challenged mice. JH-X-119-01 increases survival of mice at the dose of 5 mg/kg body weight. Survival is further improved when the dose is increased to 10 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 (20-22 g, male) mice[1]
Dosage: 5 mg/kg and 10 mg/kg
Administration: Intraperitoneally injected; 5 days
Result: Protected mice from LPS (20 mg/kg)-induced sepsis. Survival at day 5 was 13.3% in control group where septic mice were treated by vehicle, while the values were 37.5% and 56.3% for 5 mg/kg and 10 mg/kg.
分子量

452.46

分子式

C25H20N6O3
CAS 番号
Appearance

Solid

Color

Light yellow to brown

SMILES

O=C(C=C)NC1=CC=CC(C(NC2=CC=C(NC(C3=NC(C4=CC=NN4)=CC=C3)=O)C=C2)=O)=C1
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

DMSO : 100 mg/mL (221.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2101 mL 11.0507 mL 22.1014 mL
5 mM 0.4420 mL 2.2101 mL 4.4203 mL
10 mM 0.2210 mL 1.1051 mL 2.2101 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.98 mg/mL (4.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.98 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション

純度: 99.65%

COA (249 KB) HNMR (518 KB) RP-HPLC (260 KB) LCMS (96 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2101 mL 11.0507 mL 22.1014 mL 55.2535 mL
5 mM 0.4420 mL 2.2101 mL 4.4203 mL 11.0507 mL
10 mM 0.2210 mL 1.1051 mL 2.2101 mL 5.5254 mL
15 mM 0.1473 mL 0.7367 mL 1.4734 mL 3.6836 mL
20 mM 0.1105 mL 0.5525 mL 1.1051 mL 2.7627 mL
25 mM 0.0884 mL 0.4420 mL 0.8841 mL 2.2101 mL
30 mM 0.0737 mL 0.3684 mL 0.7367 mL 1.8418 mL
40 mM 0.0553 mL 0.2763 mL 0.5525 mL 1.3813 mL
50 mM 0.0442 mL 0.2210 mL 0.4420 mL 1.1051 mL
60 mM 0.0368 mL 0.1842 mL 0.3684 mL 0.9209 mL
80 mM 0.0276 mL 0.1381 mL 0.2763 mL 0.6907 mL
100 mM 0.0221 mL 0.1105 mL 0.2210 mL 0.5525 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JH-X-119-01 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JH-X-119-012227368-54-7IRAKInterleukin-1 receptor associated kinaseIL-1R associated kinaseIRAK1MYD88Waldenstr?mmacroglobulinemiaDiffused Large B-cell LymphomaInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
JH-X-119-01
製品番号:
HY-103017A
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.